Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

TheMotleyFool

0 0

Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

It's been a really good year for Exelixis (NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen (NASDAQ: IMGN): The stock has soared nearly 270%.

The past is the past, though. Which of these cancer-focused biotech stocks is the better choice for investors now? Here's how Exelixis and Immunogen compare.

Image source: Getty Images.

Source: Fool.com